Discovery of a Novel Ubenimex Derivative as a First-in-Class Dual CD13/Proteasome Inhibitor for the Treatment of Cancer

The CD13 inhibitor ubenimex is used as an adjuvant drug with chemotherapy for the treatment of cancer due to its function as an immunoenhancer, but it has limitations in its cytotoxic efficacy. The proteasome inhibitor ixazomib is a landmark drug in the treatment of multiple myeloma with a high anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jian, Sun, Simin, Liu, Jinyu, Zhang, Liang, Guo, Di, Zhang, Naixin, Zhao, Jun, Kong, Dexin, Xu, Tongqiang, Wang, Xuejian, Xu, Wenfang, Li, Xiaoyang, Jiang, Yuqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489073/
https://www.ncbi.nlm.nih.gov/pubmed/37687169
http://dx.doi.org/10.3390/molecules28176343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10489073/
https://www.ncbi.nlm.nih.gov/pubmed/37687169
http://dx.doi.org/10.3390/molecules28176343

Ejemplares similares